Small molecules and antibodies for the treatment of psoriasis: a patent review (2010-2015).
BACKGROUND
Psoriasis is a chronic condition whose therapeutic armamentarium is increasingly being discussed, particularly when compared to past decades. The use of biologic agents has profoundly changed the history of this disease, as well as the management of psoriatic patients. Due to the enormous interest in psoriasis, as demonstrated within the scientific community and pharmaceuticals, new therapeutic targets have been identified and novel patented therapeutics are being tested.


METHODS
This review sought to give an overview of small molecules and antibodies patented in the last five years for the treatment of psoriasis. Therapeutic agents either in the early or advanced phase of development have been described, primarily based on a systematic search using the PubMed Medline database.


CONCLUSIONS
Though the recent introduction of new antipsoriatic agents has facilitated the management of long-term psoriasis, there is still a strong desire for alternative therapeutic options. Indeed, there remain unmet needs regarding safety and efficacy of psoriasis treatment that should be addressed. In this context, recently patented drugs may prove valid, interesting, and promising within the therapeutic paradigm.
a Dermatology Department , University of Pisa , Pisa , Italy.
Andrea
A
Chiricozzi
b Dermatology Unit, Department of Internal Medicine , University of Rome Tor Vergata , Rome , Italy.
Rosita
R
Saraceno
c Rheumatology, Allergology and Clinical Immunology, Department of Internal Medicine , University of Tor Vergata , Rome , Italy.
Lucia
L
Novelli
d University Hospital Center Tirana , Tirana , Republic of Albania.
Monika
M
Fida
e Rheumatology Unit, Department of Clinical Medicine and Surgery , University Federico II , Naples , Italy.|f Rheumatology Unit, Department of Medicine DIMED , University of Padua, School of Medicine and Surgery , Padua , Italy.
Francesco
F
Caso
e Rheumatology Unit, Department of Clinical Medicine and Surgery , University Federico II , Naples , Italy.
Raffaele
R
Scarpa
e Rheumatology Unit, Department of Clinical Medicine and Surgery , University Federico II , Naples , Italy.
Luisa
L
Costa
c Rheumatology, Allergology and Clinical Immunology, Department of Internal Medicine , University of Tor Vergata , Rome , Italy.
Roberto
R
Perricone
a Dermatology Department , University of Pisa , Pisa , Italy.
Marco
M
Romanelli
b Dermatology Unit, Department of Internal Medicine , University of Rome Tor Vergata , Rome , Italy.
Sergio
S
Chimenti
c Rheumatology, Allergology and Clinical Immunology, Department of Internal Medicine , University of Tor Vergata , Rome , Italy.
Maria Sole
MS
Chimenti
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D001685:Biological Factors / Q000494:pharmacology / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D015195:Drug Design; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use; D010330:Patents as Topic; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology
D000911:Antibodies, Monoclonal; D001685:Biological Factors; D003879:Dermatologic Agents; D007155:Immunologic Factors
JAK-STAT; Psoriasis; TNF-α; biologic; pathogenesis; small molecules